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ABSTRACT
Rising health care spending is a source of concern in the
U.S. With new, high-cost health care technology, paying higher
prices for the use of new technology without considering cheaper,
equally effective alternatives leads to inefficient spending. This
Note focuses on proton beam therapy (“PBT”) for treatment of
prostate cancer to explore several causes that contribute to high
health care spending in the U.S. In treating prostate cancer,
PBT has not been shown to be more effective than its cheaper
alternative, IMRT. Yet, investors and many states continue to
encourage its use for prostate cancer. This Note argues that
inefficient use of PBT increased because existing standard for
review of new health care technology and its reimbursement
often suggest new health care technology will be reimbursed at a
prime rate. Hence, private investors fueled the development of
PBT Centers indiscriminately, expecting a high return on their
investment. Then, this Note proposes several ways to encourage
a more efficient use of PBT.

INTRODUCTION
The term “technology evolution” is used when a new technology
develops and improves upon an existing technology. 1 When a
technology evolution imposes much larger costs for medical treatment
than existing technology, the new technology should be evaluated
critically to examine its efficacy. This is difficult in medical technology
(“medtech”) because clinical trials often take a long time to conduct.
Often, during the time in which researchers conduct trials to demonstrate
the efficacy of a new medtech, tension arises between those who want to
encourage patient access to potentially promising treatment and those
who want to save costs until efficacy of the new technology is proven.2
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Proton Beam Therapy (“PBT”), a technology used for treating
cancer by delivering conformal external beam radiation with positively
charged atomic particles to a well-defined treatment volume,3 is an apt
example of a technology evolution. PBT is currently used to treat a
variety of cancers, but opinions about the appropriateness of its use for
different cancers vary wildly. Agreement on its effectiveness is strongest
for tumors surrounded by critical structures like the eye, brain, and spinal
cord, and for solid tumors in children.4 For other types of cancers, such
as prostate cancer, opinions diverge because currently, there isn’t much
concrete evidence. 5 Some argue that PBT is more effective than
intensity-modulated radiation therapy (“IMRT”), which is a widely
adopted treatment for prostate cancer, because of its improved precision
of the radiation beams. However, because PBT is much more costly than
IMRT, its efficacy should be assessed carefully.
This Note examines the current landscape of PBT, its use in
prostate cancer, and its efficacy as a technological evolution. Part I
compares PBT with IMRT. Part II examines PBT’s rise in use and the
reasons behind it. Part III proposes a movement to encourage a more
efficient development of PBT use, while encouraging a continuance in
research.

I. PROTON BEAM THERAPY (PBT) VS. INTENSITY-MODULATED
RADIATION THERAPY (IMRT)
To understand the efficacy of adopting PBT for the treatment of
prostate cancer, PBT must be compared to the existing alternative for
treating prostate cancer, IMRT. IMRT uses a disseminated distribution
of photon radiation to target tumors.6 Photon beams deposit the greatest
amount of energy “beneath the patient’s surface with a gradual reduction
in energy deposition” as photons pass through the target, then exit
through an exit point.7 Comparatively, PBT uses proton particles and
3
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allows “for the majority of its energy to be deposited over a very narrow
range of tissue at a depth largely determined by the energy of the proton
beam.” 8 Because the energy deposition of a proton beam rapidly
increases over a narrow range at a desired depth to produce an intense
dose, proton beam deposits relatively less radiation energy when entering
and exiting the body.9
IMRT is currently the standard form of radiotherapy for treating
prostate cancer. 10 IMRT was quickly and widely adopted when its
relative effectiveness to existing treatment was uncertain.11 In 2000,
IMRT treated less than 1% of localized prostate cancers; by 2008, it
treated 96% of prostate cancer patients.12 Its quick adoption was based
on two potential benefits: first, IMRT would deliver higher doses of
radiation to cancer sites, and second, it would reduce radiation exposure
to surrounding tissue.13 Despite IMRT’s wide adoption, its superiority
and cost-effectiveness over the alternative treatment still was being
studied in 2010.14
Similar to the adoption of IMRT, many health care providers
quickly adopted PBT as a treatment for prostate cancer despite its
uncertainty. PBT gained popularity as a prostate cancer treatment based
on the potential theory that it benefits prostate cancer patients by
reducing the amount of radiation that surrounding organs receive. 15
8
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However, studies have failed to demonstrate that PBT provides better
outcomes than IMRT for prostate cancer patients.16 A study reviewing
Medicare records of nearly 55,000 prostate cancer survivors found that
PBT is associated with small reductions in urinary effects, but only
within the first six months of treatment.17 After that, researchers found
no difference in side effects between patients treated with PBT and those
treated with IMRT.18
Some studies actually suggest that PBT may result in more
toxicity than IMRT because PBT has greater physical and biological
uncertainties than IMRT. 19 This means that PBT may be more prone to
errors related to patient set up, positioning, and organ movement during
treatment.20 A 2012 study of long-term morbidity found that localized
prostate cancer patients who received PBT had a higher rate of
gastrointestinal morbidity than those who received IMRT. 21 The
researchers found no other significant differences in rates of other
morbidities between IMRT and PBT.22
In addition to uncertainty over its relative efficacy and possible
toxicity, cost is an issue with PBT. Despite the lack of evidence of its
superiority, PBT treatment can cost 48,000 dollars or more, while IMRT
treatment costs around 20,000 dollars.23 PBT treatment is expensive
because PBT Centers require a huge capital cost. Construction of earlier
PBT Centers, which were the size of a football field with concrete walls

in Localized Prostate Cancer, 307 J. AM. MED. ASS’N 1, 7 (2012) (“[PBT]
relative to IMRT may reduce the proportion of each surrounding organ that
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20
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up to thirteen feet thick, 24 cost between 120 million and 250 million
dollars.25
Although lack of demonstrable efficiency and cost-effectiveness
are problems with PBT, there are benefits to allowing further research.
Prostate cancer is slow-developing. Complete studies about long-term
effectiveness of PBT can take decades to develop. For example, research
demonstrated IMRT’s effectiveness for prostate cancer treatment years
after its adoption. Presently, only a few randomized control trials or
well-conducted cohort studies comparing PBT to other treatments exist.26
Although irresponsible spending must be avoided, in order to form an
informed judgment about PBT use in prostate cancer, researchers must
be able to continue their research about PBT’s effectiveness in prostate
cancer treatment.

II. EXPECTATION OF DEMAND, PROFIT, AND THE RISE OF PBT
Use of PBT for prostate cancer accounts for an increasing
portion of Medicare spending. PBT use for prostate cancer increased
drastically since 2006, increasing by 68 percent from 2006 to 2009.27
From 2010 to 2016, Medicare spending for PBT increased from 47
million to 115 million dollars.28 Prostate cancer treatment is the most
common use of PBT and accounts for almost half the spending and
volume. 29 It is also the most expensive. Average total Medicare
reimbursements ranged from about 5,000 dollars for ocular tumors to
24

Matt Goodman, How a Cyclotron Saves Lives, D MAG. (Oct. 2015),
https://www.dmagazine.com/publications/d-magazine/2015/october/cyclotroncancer-fighting-machine/.
25
See Ezekiel J. Emanuel and Steven D. Pearson, It Costs More, But Is It Worth
More?, N.Y. TIMES: OPINIONATOR (Jan. 2, 2012),
https://opinionator.blogs.nytimes.com/2012/01/02/it-costs-more-but-is-it-worthmore/ (stating that PBT Centers cost $180 million); Glennda Chui, The Power of
Proton Therapy, SYMMETRY (Dec. 1, 2008),
https://www.symmetrymagazine.org/article/december-2008/the-power-ofproton-therapy (“[PBT Centers] cost in the neighborhood of $120 million to
$180 million . . . .”); Bonnie Berkowitz & Aaron Steckelberg, How Proton
Therapy Attacks Cancer, WASH. POST (Mar. 30, 2018),
https://www.washingtonpost.com/graphics/2018/health/proton-beamtherapy/?utm_term=.390e8cd25d03 (stating that PBT Centers cost $200 million
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26
See Jarosek et al., supra note 4, at 1.
27
Id. at 2, 8.
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MEDICARE PAYMENT ADVISORY COMM’N, MEDICARE COVERAGE POLICY AND
USE OF LOW-VALUE CARE 294 (June 2018).
29
Id. at 323.
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25,000 dollars for prostate cancer.30 This rate of reimbursement is also
much higher than the rate of reimbursement for IMRT.31
PBT Centers are extremely costly and treating a high patient
volume is the only way to recover construction costs.32 Because prostate
cancer is one of the most common33 and one of the most generously
reimbursed cancers, treating prostate cancer patients is one of the ways in
which PBT Centers can profit. With over 150,000 new cases diagnosed
every year,34 even a small percentage of prostate cancer patients seeking
to use PBT would lead to a large increase in the use of the technology.35
In fact, statistics suggest that PBT Centers do rely on prostate cancer
patients to increase their patient volume. Within the region of referral, 9
percent of prostate cancer patients received PBT treatment for their
prostate cancer. 36 For patients outside the region of referral, only 2
percent of the patients received PBT.37 This shows that PBT Centers are
looking for ways to doing more procedures.38
Investors and hospitals alike investing in PBT Centers relied on
the assumption that PBT Centers will treat large numbers of prostate
cancer patients and insurers will generously reimburse that.39 Hospitals
30

Jarosek et al., supra note 4, at 5.
See Kilian C. Schiller et al., Protons, Photons, and the Prostate—Is There
Emerging Evidence in the Ongoing Discussion on Particle Therapy for the
Treatment of Prostate Cancer?, 6 FRONTIERS IN ONCOLOGY 1, 5 (Jan. 28, 2016),
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729886/ (stating that
reimbursement for PBT is almost twice as high as that for IMRT).
32
See Jenny Gold, Proton Beam Therapy Heats Up Hospital Arms Race,
KAISER HEALTH NEWS (May 31, 2013), https://khn.org/news/proton-beamtherapy-washington-dc-health-costs/.
33
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AND DEATHS, MALE AND FEMALE, 2016,
https://gis.cdc.gov/Cancer/USCS/DataViz.html (last visited March 25, 2020)
(showing that, in 2016, prostate cancer was the second most common cancer to
develop).
34
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STATISTICS, https://www.cdc.gov/cancer/prostate/statistics/index.htm (last
visited May 11, 2019) (see information on main page, then click on “trends”).
35
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MEDSCAPE (Jan. 30, 2013),
https://www.medscape.com/viewarticle/778466#vp_2.
37
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See id. (quoting a doctor who states that because PBT Centers have excess
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39
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built their centers with equity and bank loans, expecting to make profits
and high returns for equity investors.40 Some hospitals partnered with
for-profit developers to fund the construction of a PBT Center.41 Under
the assumption that they would treat a large percentage of prostate cancer
patients, PBT Centers anticipated treating more than 85 patients per
day.42 Some Centers, such as the Maryland Proton Therapy Center,
expected to treat about 70 prostate cancer patients a day.43
Then-existing legal and legislative structures surrounding
reimbursements for health technology revolution supported this
expectation.
Structurally, Medicare typically reimburses new
technologies without scrutinizing their cost-effectiveness. Medicare’s
decision typically affects reimbursement from private insurers as well,
because private insurers traditionally follow Medicare’s lead for
reimbursing for new technology.44 Further, there has been an increase in
legislatively mandated review processes of medical necessity denials.45
Some states’ regulations even specifically require insurers to defer to the
judgment of physicians.46
In addition, under a theory of breach of contract, insurers face
potential liability for denying coverage for procedures.47 Traditionally,
where insurance companies’ policies stated that they do not cover
“experimental” technology, most courts employed the ambiguities rule,
stating that “experimental technology” was an ambiguous term and
interpreting it to favor reimbursement.48 In other cases, courts used the
40

See Hancock, supra note 23; David Whelan & Robert Langreth, The $150
Million Zapper, FORBES (Feb. 26, 2009),
https://www.forbes.com/forbes/2009/0316/062_150mil_zapper.html#85a9bf820
68f.
41
See, e.g., Gold, supra note 32 (stating that the Baltimore facility is funded by
a for-profit developer, Advanced Particle Therapy).
42
See Hancock, supra note 23.
43
See Gold, supra note 32 (stating that Maryland Proton Therapy Center
anticipated treating about 200 patients a day, 35% of which would be prostate
cancer patients).
44
See Wendy Netter Epstein, The Health Insurer Nudge, 91 S. CAL. L. REV. 595,
598, 617–18, 620–22 (2018) (citing Bradley Sawyer & Cynthia Cox, How Does
Health Spending in the U.S. Compare to Other Countries?, PETERSON-KAISER:
HEALTH SYSTEM TRACKER (Feb. 13, 2018),
https://www.healthsystemtracker.org/chart-collection/health-spending-u-scompare-countries/#item-start).
45
See Epstein, supra note 44, at 623.
46
See id.
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See id. at 624–25.
48
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reasonable expectations test: where the insurance policy did not clearly,
conspicuously and plainly notify the insured that the disputed technology
would not be covered, courts expanded insurance coverage to include the
new technology.49
To the surprise of many, however, PBT Centers’ profit from
prostate cancer patients has not lived up to the investors’ expectations,
and many PBT Centers are struggling recoup their large capital cost.50 In
2013, several major insurers stopped reimbursing PBT use in treating
prostate cancer. 51 Medicare patients alone have been insufficient to
recoup the massive capital cost of PBT Centers.52 In 2014, Indiana
University’s PBT Center became the first facility to close.53 A number
of other PBT Centers followed, closing their facilities or restructuring in
bankruptcy courts.54
Many PBT Centers are adapting to the changing landscape.
Some new centers are smaller, with one or two treatment rooms
compared to four or five.55 Smaller PBT Centers can cost less than 50
million dollars,56 which lessens the burden on the Centers to recoup its
capital cost by treating a large volume of patients. Some Centers are
adapting by modifying their pricing system: University of Pennsylvania,
the Mayo Clinic and University of Maryland, for example, have set the
price of PBT equal to IMRT while researchers continue to examine the
effectiveness of PBT for prostate cancer.57 Others, such as Northwestern
Proton Therapy, Provision CARES Cancer Center and the Seattle Cancer
Alliance, have payment programs for patients where the Center, not the
patients, takes on the financial risk if PBT is not covered by insurance on
appeal.58 Other efforts are being conducted to make PBT treatment
cheaper and more efficient. Several manufacturers, including Mevion
Medical Systems, Hitachi, and Varian Medical Systems, are invested in
49

Id. at 1102.
Hancock, supra note 23.
51
Melinda Beck, Big Bets on Proton Therapy Face Uncertain Future, WALL ST.
J. (May 26, 2015), https://www.wsj.com/articles/big-bets-on-proton-therapyface-uncertain-future-1432667393.
52
Hancock, supra note 23.
53
Id.
54
Id.
55
Hancock, supra note 23; see Beck, supra note 51.
56
Hancock, supra note 23; see Beck, supra note 51.
57
Janet Weiner, How to Pay for Proton Therapy in Cancer Clinical Trials,
PENN LDI BLOG (July 20, 2018), https://ldi.upenn.edu/healthpolicysense/howpay-proton-therapy-cancer-clinical-trials.
58
Berkelman et al., supra note 19, at 2462.
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building compact PBT systems that cost much less than traditional
systems.59 Studies are under way to find new ways to make PBT faster,
more agile, and more compact.60
On the other hand, some PBT Centers continue to cast their bets
on profiting from treating high volume of prostate cancer patients. As of
2018, there were 27 PBT units in the U.S. and more than 20 Centers
under construction or in development.61 A PBT Center that opened in
Manhattan in 2019 cost 300 million dollars62 and expects to treat around
1,400 patients annually. 63 Out of those 1400 patients, the Center
anticipates that 20 percent will be prostate cancer patients.64

III. PROPOSED METHODS TO CURTAIL EXPECTATIONS
The legal and legislative systems should aim to curb
uncontrolled and inefficient development of new health care technology.
For starters, they should clearly establish guidelines around
reimbursement of new health care technology and promote cost-effective
development. Further, the federal and state governments should reconsider federal and state regulations that limit competition of PBT
Centers.

A. Federal Government
Uniform federal regulation signaling more rigorous
scrutiny of inefficient, wasteful use of medical technology would
help control the expectation of profit-seeking parties and to
mitigate state regulation encouraging inefficient use. Currently,
the FDA’s approval of and Medicare’s reimbursement processes
59

See Beck, supra note 51.
Researchers Aim to Develop Radiation Therapy with Short Exposure Times,
STAN. MED. NEWS CTR. (Jan. 9, 2019), http://med.stanford.edu/news/allnews/2019/01/researchers-aim-to-develop-radiation-therapy-with-shortexposure.html.
61
Id.
62
Charles B. Simone, New York Proton Center Advances Mesothelioma
Treatment, ASBESTOS.COM (Aug. 30, 2019),
https://www.asbestos.com/blog/2019/08/30/new-york-proton-center-formesothelioma/.
63
Melanie Grayce West, New York’s First Proton Therapy Center to Open in
July, WALL ST. J. (May 16, 2019), https://www.wsj.com/articles/new-yorksfirst-proton-therapy-center-to-open-in-july-11558030007.
64
Barbara Benson, Meet Harlem’s $238 Million Cancer Killer, CRAIN’S N.Y.
BUS. (Mar. 20, 2015),
https://www.crainsnewyork.com/article/20150320/HEALTH_CARE/150329991
/meet-harlem-s-238-million-cancer-killer.
60
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for new technology does not identify unnecessary care, tending to
cover new technologies for procedures without demanding
demonstrated effectiveness.65
The FDA should enforce a more stringent device reviews
processes of new health technology to assess their safety and
effectiveness. During the initial approval process, for many categories of
health care technology, the FDA does not require randomized studies
showing its safety or effectiveness for approval. 66 Instead, most
categories of medical devices are subject to a 510(k) approval process,
which only require preclinical studies––studies done in laboratory
settings, unlike clinical studies which involve humans––or that it is
“substantially equivalent” to an existing, already-approved medical
device.67 As a result of this lenient approval process, several alarming
failures have taken place.68 The post-approval studies (PAS), which
allow the FDA to obtain information about “device safety, effectiveness,
and/or reliability over long-term use of the device[,]” have not been
rigorously enforced, either.69
The FDA should subject PBT to a higher standard of review to
ensure its safety and effectiveness. Since approving PBT for cancer
treatment in 1988, the FDA has cleared numerous developments in PBT
units for marketing under the substantial equivalence review standard of
510(k) without considering cost-effectiveness or effectiveness of the
technology for certain uses.70 Some leniency in initial FDA approval
65

See Epstein, supra note 44, at 622.
See Alan M. Garber, Modernizing Device Regulation, 362 NEW ENG. J. MED.
1161, 1161–62 (Apr. 1, 2010) (stating that for class I, class II, and some class III
medical devices, clinical trials to show their safety and efficacy are unnecessary
for FDA approval); JUDITH A. JOHNSON, CONG. RESEARCH SERV., FDA
REGULATION OF MEDICAL DEVICES 2–3 (Sept. 14, 2016) (naming recent FDA
approved medical devices that caused patient injury and death, including metalon-metal hip plants, pacemakers, defibrillators).
67
See JOHNSON, supra note 66, at 19–25 (describing the 510(k) process and
stating that many types of 510(k) processes are less rigorous than PMA process).
68
See id. at 2–3 (naming recent FDA approved medical devices that caused
patient injury and death, including metal-on-metal hip plants, pacemakers,
defibrillators); Garber, supra note 66, at 1162 (mentioning defibrillators that
have gone through PMA approval process but caused serious harm to patients by
failing to discharge or discharging inappropriately).
69
Id. at 11.
70
See U.S. FOOD & DRUG ADMIN., 510(K) SUMMARY FOR RADIATION THERAPY
BEAM-SHAPING APERTURE AND RANGE COMPENSATOR APPROVAL (Oct. 23,
2012); U.S. FOOD & DRUG ADMIN., 510(K) SUMMARY MEVION S250I
APPROVAL (Dec. 27, 2017); Hitachi Receives FDA Clearance for Probeat
66
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processes is necessary to allow consumers to have quick access to new
and improved medical devices. 71 However, when the FDA first
approved PBT, there were minimal studies available about the
effectiveness of IMRT and studies had not yet demonstrated that PBT
may be riskier than IMRT.72 The landscape of research showing PBT’s
safety and effectiveness compared to IMRT is currently different. 73
Therefore, if the FDA enforced a more stringent PAS and re-reviewed
the safety and effectiveness of PBT in comparison to IMRT, it may lead
to a re-consideration about whether PBT should continue to be used
without restrictions for treating prostate cancer.74
Medicare’s reimbursement procedures present a similar issue.
“Medicare performs no evaluation of the benefits associated with new
medical technologies, and in its fee-for-service incarnation does not ask
if care could be better managed.”75 Medicare is also very slow to update
its coverage decisions. 76 Hence, Medicare tends to discourage costsaving innovation and efficient insurance coverage denials.77
In 2017, American Society for Radiation Oncology (ASTRO)
proposed a policy for PBT. The ASTRO model suggests that until
further findings demonstrate its safety and effectiveness, the use of PBT
for prostate cancer should only be reimbursed when it is used as a part of
a clinical trial furthering research.78 This strikes the balance between
discouraging uncontrolled, irresponsible and profit-seeking development
PBT and allowing reimbursement for the use of PBT where it is apt and
helpful for further research. Several private insurers have since adopted
this model. 79 So far, however, Centers for Medicare & Medicaid
Proton Beam Therapy System, HITACHI (Mar. 21, 2006),
http://www.hitachi.us/press/03212006 (stating that as one of three PBT Centers
that are hospital-based in the U.S. at the time, it received FDA approval under
substantial equivalence standard).
71
JOHNSON, supra note 66, at 2.
72
See supra notes 15–16 and accompanying text.
73
See supra Part I.
74
See Garber, supra note 66, at 1163.
75
Baicker et al., Saving Money or Just Saving Lives? Improving the
Productivity of US Health Care Spending, 4 ANN. REV. ECON. 33, 40–41 (Apr. 5,
2012).
76
Epstein, supra note 44, at 622.
77
Baicker et al., supra note 75, at 41.
78
ASTRO Updates Insurance Coverage Recommendations for Proton Therapy,
AM . SOC’Y FOR RADIATION ONCOLOGY (July 12, 2017),
https://www.astro.org/News-and-Publications/News-and-Media-Center/NewsReleases/2017/ASTRO-updates-insurance-coverage-recommendations-f.
79
AM . SOC’Y FOR RADIATION ONCOLOGY supra note 3, at 4.
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Services (CMS) has not released a national coverage determination for
PBT, leaving reimbursement decisions up to Local Medicare
Administrative Contractors (LCDs).80
Instead of relying on state Medicare decisions, the national CMS
should state that use of PBT in prostate cancer will only be reimbursed
when it is a part of a clinical trial until further findings demonstrate its
safety and effectiveness. A clear guidance from the national CMS could
encourage an exercise of prudence from those seeking to invest in, or
develop, PBT Centers expecting to quickly recoup the high investment.
At the least, it could encourage PBT Centers to develop on a smaller and
cheaper scale or seek funding from non-profit entities so they can focus
on patient care and research rather than profit. Decreased pressure from
investors to recoup the costs would allow PBT Centers to be more
flexible with the use and price of PBT. For instance, the Mayo Clinic
built its PBT Center financed by a 100-million-dollar donation rather
than relying on private equity.81 The lack of pressure from investors
allows the Mayo Clinic to charge the same rates for PBT as for IMRT.82
Further, the federal government should preempt state regulations
which retard the movement towards efficient use of PBT. For example,
some state bills discourage private insurers from declining coverage of
PBT treatment for prostate cancer for lack of evidence demonstrating
effectiveness.83 In 2015, Oklahoma’s bill prohibited health benefit plans
from “holding [PBT] to a higher standard of clinical evidence for
medical policy benefit coverage decisions than the health plan requires
for coverage of any other radiation therapy treatment.”84 Senator Marian
Cooksey, the author of the bill, stated that insurance companies’ decision
to not reimburse PBT because of its lack of long-term studies is a “very
80

Jarosek et al., supra note 4, at 2; see e.g., FALLON HEALTH, PROTON BEAM
THERAPY CLINICAL COVERAGE CRITERIA 2 (Apr. 1, 2018),
https://www.fchp.org/en/providers/criteria-policies-guidelines/medicalpolicies.aspx (click on Proton Beam Therapy to download) (stating that
coverage for Medicare based plans is in accordance with Medicare Local
Coverage Determination).
81
See Beck, supra note 51.
82
See id.
83
Cf. Daniel Siegal, Aetna Owes $26M Over Denied Cancer Treatment, Jury
Says, LAW360 (Nov. 8, 2018), https://www.law.com/2018/11/14/25-6m-oklaverdict-against-aetna-in-denied-treatment-case-raises-bad-faithissues/?slreturn=20190022132147 (finding the insurance company to be in bad
faith for repeatedly refusing to cover PBT for a patient’s tumor in her throat and
awarding nearly $25.6 million in damages including punitive damages).
84
See H.B. 1515, 2015 Leg., 1st Sess. (Okla. 2015).
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weak argument.”85 Oklahoma law, in turn, “ensur[es] that the physician
has the final say in the treatment, not the insurance company.”86
Another example of an inefficient state regulation is State
Certificate of Need (CON) law, which regulates medtech. State CON
laws require health care providers to obtain a permit from the state before
offering new services, constructing new buildings, or purchasing new
medical equipment. 87 Once upon a time, the federal government
supported CON laws and considered them to be cost-containment
mechanisms.88 But, over time, CON laws were found to have the
opposite effect. When states enacted CON laws, their Medicare
spending increased by 6.9 percent because the CON laws restricted the
supply of health care. 89 When repealed, state health care spending
decreased by .8 percent per year, leveling out at 4 percent after five years.
90
The federal government has spoken out against state CON laws.91
The FTC stated that CON laws “create barriers to expansion, limit[s]
consumer choice, and stifle[s] innovation.”92
Despite the statistics, 35 states and the District of Columbia
continue to enforce CON laws for at least some health care services.93
Some states specifically proposed regulation to limit the number of PBT
Centers in the state.94 Even if state CON laws are not aimed specifically
85

New Law Will Protect Proton Therapy Coverage, OK HOUSE,
https://www.okhouse.gov/Media/ShowStory.aspx?MediaNewsID=5045 (last
visited Sept. 22, 2019).
86
Id.
87
Emily Whelan Parento, Certificate of Need in the Post-Affordable Care Act
Era, 105 KY. L.J. 201, 205 (2017).
88
See id. at 205, 207 (stating that the federal government first perceived CON
laws to be cost-containing mechanisms and required states to enact CON laws
for a brief period in 1970s and 1980s).
89
James Bailey, Can Health Spending Be Reined in Through Supply Constraints?
An Evaluation of Certificate-of-Need Laws, MERCATUS CTR. (Aug. 1, 2016),
https://www.mercatus.org/publication/health-spending-reined-in-CON-laws.
90
Id.
91
See Parento, supra 87, at 215 (stating that the federal government has not been
neutral towards CON laws and that both the FTC and DOJ have spoken out
against it).
92
Agencies Submit Joint Statement Regarding Virginia Certificate-of-Need
Laws for Health Care Facilities, FEDERAL TRADE COMM’N (Oct. 26, 2015),
https://www.ftc.gov/news-events/press-releases/2015/10/agencies-submit-jointstatement-regarding-virginia-certificate.
93
Parento, supra note 87.
94
Jay Greene, Local Proton Beam Planners March On: McLaren Rivals Say
Need Supports Multiple Centers, CRAIN’S DETROIT BUS., (Sept. 29, 2009),
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to control PBT Centers, operation of PBT facilities often does not pass
regulatory muster without approved CON.95
The FTC should enforce antitrust laws against states that adopted
CON laws where they are violative of federal antitrust laws. Requiring
PBT units to obtain a CON before operating in a state harms consumers
by “creat[ing] market power” and “limit[ing] patient choice” and
“creat[ing] opportunities for existing competitors to thwart or delay new
competition.”96 Under CON law, once a state allows the development of
one PBT Center, other PBT Centers face extremely high barriers to enter
the market. 97 This effectively tells the PBT Centers that once they
establish a large Center in a state and becomes approved under CON law,
they are not likely to have competition. This can have negative effects
on cancer patients because this limits patient choice and excludes
cheaper, or more superior, alternatives that a competitive market may
offer.98
Additionally, with little room to enter the market, new actors
lack incentive to find cheaper methods of entry.99 Higher barriers of
entry into the market therefore impede efforts to improve the efficiency
https://www.crainsdetroit.com/article/20090929/EMAIL01/309299993/localproton-beam-planners-march-on-mclaren-rivals-say-need (stating that in 2008,
Michigan Certificate of Need Commission approved regulation to limit the
number of PBT Centers to a single collaborative of five hospitals).
95
See Memorandum regarding Proton Beam Therapy from Thomas Jung, Acting
Director of the Division of Heath Facility Planning of New York to Members of
the State Hospital Review and Planning Council (Mar. 11, 2010),
https://www.health.ny.gov/facilities/cons/proton_beam_therapy_demonstration_
project/docs/memorandum.pdf (addressing the question whether operating a
PBT facility requires CON approval and concluding that it’s difficult, if not
impossible, to imagine a PBT facility that would pass regulatory muster without
CON approval).
96
See, e.g., U.S. DEP’T OF JUSTICE, ANTITRUST DIV., COMMENTS ON PROPOSED
CERTIFICATE OF NEED STANDARDS FOR PROTON BEAM THERAPY SERVICES,
https://www.justice.gov/atr/comments-proposed-certificate-need-standardsproton-beam-therapy-services (June 6, 2008).
97
See id.(stating that the proposed CON law allows for only one PBT Center to
operate, and in addition, the approved entities may set terms and standards of
operation for other seeking to enter the market, and existing entities may thwart
or delay new competition).
98
See id.(“[CON] law regimes, by their nature, limit competitive entry and
impede the proper functioning of the market process. They can create market
power where it may not otherwise exist, limit patient choice, and create
opportunities for existing competitors to thwart or delay new competition”).
99
See id.

383

HIGH HEALTH CARE SPENDING
AND DEVELOPING TECHNOLOGY:
PROTON BEAM THERAPY

[Vol. 18

or cost of PBT. In a 2014 report, Ernst & Young (EY) compared the
medtech market to the personal computer industry in the 90s, arguing
that low barriers to market entry for the personal computer industry
encouraged and accelerated the development of the market.100 Lowering
barriers to market entry in the PBT market is likely to promote
development of already existing efforts 101 to make PBT units faster,
cheaper, and more efficient by encouraging “reverse innovation”––
finding ways to produce relatively inexpensive, stripped-down versions
of the units––and encouraging international manufacturers to seek to
enter the U.S. market as well.102

The presence of CON law affects the behavior of existing
PBT Centers and their interaction with potential patients as well.
With the rising health care costs in the U.S. continuing to be a
looming issue, the medical health technology field is shifting its
focus. Hospitals are increasingly shifting simple cost-cutting to
increasing value, 103 and health care purchasers are prioritizing
devices that reduce the total cost of care.104 “Payers and providers
are most interested in highly differentiated medtech products that
represent a significant improvement over the standard of care.” 105
PBT, without further research on its effectiveness or the value of
its technology transfer from IMRT, is more likely to be scrutinized
under this focus. Increasing competition is likely to encourage
PBT Centers to find ways to cut costs and find ways to make PBT
treatment more efficient.

100

ERNST & YOUNG, PULSE OF THE INDUSTRY: MEDICAL TECHNOLOGY REPORT
9 (2014).
101
See supra notes 59 and 60 and accompanying text.
102
See generally ERNST & YOUNG, supra note 100.
103
See id. at 6.
104
Id. at 8.
105
Id.
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B. Insurance Companies
Private insurers have been playing a key role in curbing PBT
reimbursement. In defiance of their traditional ways, insurance
companies have declined to reimburse PBT treatment of prostate
cancer. 106 In 2013, three major insurers––Regence, Blue Shield of
California, and Aetna––changed their policies to stop covering PBT for
prostate cancer, stating that PBT is more costly but without demonstrated
increased benefits compared to IMRT. 107 Currently, nearly all
commercial insurers and state Medicaid plans do not cover PBT for
prostate cancer.108
Several recent court decisions have supported the insurance
companies’ decisions to deny coverage for the use of PBT in prostate
cancer. In Baxter v. MBA Group Ins. Trust Health and Welfare Plan,109
the plaintiff patient brought a claim for wrongful denial of coverage
against his insurance after being denied reimbursement for PBT for early
state prostate cancer. His insurance plan stated that PBT was not
“medically necessary” as stated by their medical policy because it has
not been shown to be superior to other approaches.110 Finding that the
burden of proof was on the plaintiff to establish medical necessity, the
effectiveness of PBT, and the cost of PBT, the court granted the
insurance company’s motion for summary judgment.111
Similarly, in Woodruff v. Blue Cross and Blue Shield of
Alabama,112 the plaintiff claimed that Blue Cross Blue Shield (BCBS)
wrongfully denied his claim for reimbursement of PBT treatment for his
prostate cancer. The court granted BCBS’s motion for summary
judgment, concluding that the court’s role was only to decide whether
BCBS’s judgment was “reasonable.” 113 There, the court found that
BCBS’s decision to deny coverage was reasonable based on the lack of
randomized, published studies showing that it is superior to its
106

Ron Winslow & Timothy W. Martin, Prostate-Cancer Therapy Comes
Under Attack, WALL ST. J. (Aug. 28, 2013),
https://www.wsj.com/articles/prostatecancer-therapy-comes-under-attack1377734990?tesla=y; Jaimy Lee, As a Proton Therapy Center Closes, Some See
It as a Sign, MODERN HEALTHCARE (Sept. 18, 2014),
https://www.modernhealthcare.com/article/20140918/NEWS/309189939.
107
See Winslow & Martin, supra note 106.
108
Bekelman et al., supra note 19.
109
958 F. Supp. 2d 1223 (W.D. Wash. 2013).
110
Id. at 1225.
111
Id. at 1230–38.
112
2018 WL 571933 (N.D. Ala. Jan. 26, 2018).
113
Id. at *7.
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alternatives.114 The court further found that the opinions of a treating
physician were not “entitled to a presumption of deference.” 115 In
Howard v. Blue Cross and Blue Shield of Arizona,116 too, the district
court upheld the insurer defendant’s denial of PBT use in prostate cancer,
finding that the insurer defendant was not “clearly erroneous” in finding
that PBT use in the plaintiff’s case was not “medically necessary.”
In all three cases, courts refer specifically to the language in the
insurance plan. In Woodruff and Howard, the insurer defendants clearly
stated that “medically necessary” encompasses considerations of cost.117
The Woodruff and Howard insurer defendants further stated in their
policy that under their “medically necessary” definition, PBT for prostate
cancer was not covered.118
Because insurance policies are read as contracts, where the
definition of “medically necessary” is clearly stated to include costeffectiveness, or PBT is specifically listed in the plan as a non-medically
necessary treatment based on existing evidence, courts may be less likely
to inject their own patient-friendly, broad definitions of “medical
necessity.” Therefore, until there are sufficient studies on PBT use for
localized prostate cancer that support its cost compared to that of IMRT,
courts may continue to rule in the insurer’s favor if the insurance plan
includes the right language. This may help curb PBT Centers’ reckless
114

Id. at *10.
Id. at *8.
116
Howard v. Blue Cross Blue Shield of Ariz., No. CV-16-03769-PHX-JJT,
2019 U.S. Dist. LEXIS 116058 (D. Ariz. July 12, 2019).
117
See Woodruff, 2018 WL 571933, at *6 (“If a service or supply is not
addressed . . . it will be considered to be medically necessary only if . . . it is
appropriate and necessary . . . and performed in the least costly setting, method,
or manner, or with the least costly supplies required by [the patient’s] medical
condition.”); Baxter v. MBA Grp. Ins. Tr. Health and Welfare Plan, 958 F. Supp.
2d 1223, 1228–29 (W.D. Wash. 2013) (“[I]n accordance with generally accepted
standards of medical practice; clinically appropriate . . . ; not more costly than
an alternative service or sequence of services or supply at least as likely to
produce equivalent therapeutic or diagnostic results . . . .”).
118
See Woodruff, 2018 WL 571933, at *6 (“[PBT] does not meet [BCBS’s]
medical criteria for coverage in patients with clinically localized prostate cancer,
because the clinical outcomes with this treatment have not been shown to be
superior to other approaches including [IMRT] yet proton beam therapy is
generally more costly . . . .”); Howard, 2019 U.S. Dist. LEXIS 116058, at *9
(“[PBT] is considered not medically necessarily for clinically localized prostate
cancer based upon insufficient evidence to support improvement of the net
health outcome, and insufficient evidence to support improvement of the net
health outcome as much as, or more than, established alternatives.”).
115
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use of PBT for prostate cancer without substantiating its safety or
effectiveness.
At the same time, a complete ban on coverage of PBT use by
private insurers is likely premature. One of the problems with PBT is
that there are no randomized trials showing its effectiveness. But,
conducting randomized trials is difficult if there are not enough patients
to participate in the trials.119 Lack of reimbursements for PBT can result
in lack of enrollment of patients in clinical trials that may provide
concrete answers about the long-term effectiveness of PBT. Coverage
from Medicare helps, but the number of patients who can participate
would be significantly limited. 120 Additionally, Medicare includes
mostly patients over 65, which may reduce the generalizability of the
results.121
To deal with this dilemma, some insurers cover PBT for selected
cancers being studied to support clinical trials.122 For example, Cigna,
Independence Blue Cross, and Blue Cross Blue Shield of Florida cover
PBT for selected cancers under study or have established coverage with
study participation policies.123 This practice curbs irresponsible use of
PBT treatment but allows clinical trials to continue their research on
PBT’s effectiveness and safety. In the past, continued use of IMRT,
despite its lack of demonstrated effectiveness, allowed clinical trials to
continue their studies, which ultimately proved IMRT to be an effective
method of treatment for prostate cancer. Such results would have been
close to impossible had patients been unable to afford IMRT. Therefore,
rather than implement a total ban on reimbursement of PBT, private
insurers should consider the policy of reimbursing those participating in
clinical trials.

CONCLUSION
Uncontrolled and unregulated health care spending on new
technology without adequate findings of its effectiveness takes away
funds that could be spent efficiently elsewhere. PBT demonstrates
promise for various types of cancers, but so far, for localized prostate
cancer, there is a significant lack of research showing its effectiveness
compared to its alternatives.
119

Weiner, supra note 57.
Why Randomized Trials for Proton Therapy are Difficult to Complete (and
What We Can Do About It), SCI. DAILY (July 11, 2018),
https://www.sciencedaily.com/releases/2018/07/180711141353.htm.
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The U.S. has seen a rise in the number of PBT Centers and the
use of PBT, mainly driven by the anticipated profit stemming from the
its use for treatment of prostate cancer. This expectation was likely
fostered by the existing environment facilitating generous reimbursement
for new medical technology. Despite the recent financial problems that
existing PBT Centers have experienced, many PBT Centers continue to
build, still anticipating high patient volume from prostate cancer patients.
Curtailing the expectation of demand and profit by establishing a level of
scrutiny towards inefficient use of PBT on a federal level is likely to
encourage a more efficient growth of the PBT market.

